Carl Zeiss Meditec AG

OTCPK:CZMW.F Stock Report

Market Cap: US$9.4b

Carl Zeiss Meditec Valuation

Is CZMW.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CZMW.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CZMW.F ($99.55) is trading above our estimate of fair value ($98.99)

Significantly Below Fair Value: CZMW.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CZMW.F?

Other financial metrics that can be useful for relative valuation.

CZMW.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA24.9x
PEG Ratio2.6x

Price to Earnings Ratio vs Peers

How does CZMW.F's PE Ratio compare to its peers?

The above table shows the PE ratio for CZMW.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average59.4x
TFX Teleflex
32.3x18.8%US$9.4b
PEN Penumbra
88.9x24.5%US$8.0b
PODD Insulet
59.2x17.5%US$12.1b
GMED Globus Medical
57.1x31.3%US$6.8b
CZMW.F Carl Zeiss Meditec
31.5x11.9%US$8.7b

Price-To-Earnings vs Peers: CZMW.F is good value based on its Price-To-Earnings Ratio (31.5x) compared to the peer average (59.4x).

Price to Earnings Ratio vs Industry

How does CZMW.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: CZMW.F is good value based on its Price-To-Earnings Ratio (31.5x) compared to the US Medical Equipment industry average (36.4x).

Price to Earnings Ratio vs Fair Ratio

What is CZMW.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CZMW.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CZMW.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CZMW.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$99.55
US$116.18
+16.7%
18.4%US$160.38US$74.84n/a15
Apr ’25US$118.26
US$114.82
-2.9%
21.8%US$163.31US$64.24n/a15
Mar ’25US$124.75
US$110.60
-11.3%
19.7%US$151.91US$64.02n/a14
Feb ’25US$109.50
US$106.18
-3.0%
21.4%US$152.36US$56.59n/a14
Jan ’25US$107.29
US$105.48
-1.7%
20.6%US$152.84US$56.77n/a13
Dec ’24n/a
US$112.11
0%
16.9%US$152.26US$80.48n/a12
Nov ’24US$82.38
US$111.72
+35.6%
14.9%US$147.93US$91.93n/a11
Oct ’24US$88.00
US$121.54
+38.1%
19.3%US$187.63US$93.28n/a11
Sep ’24n/a
US$124.35
0%
19.6%US$190.28US$94.60n/a11
Aug ’24US$115.62
US$141.75
+22.6%
17.9%US$194.77US$100.17n/a11
Jul ’24n/a
US$142.63
0%
16.8%US$191.07US$98.26n/a11
Jun ’24US$116.00
US$142.63
+23.0%
16.8%US$191.07US$98.26n/a11
May ’24US$137.25
US$147.29
+7.3%
18.7%US$191.97US$98.73US$111.2011
Apr ’24n/a
US$147.98
0%
22.9%US$205.72US$80.18US$118.2611
Mar ’24US$138.50
US$147.98
+6.8%
22.9%US$205.72US$80.18US$124.7511
Feb ’24US$139.25
US$147.05
+5.6%
24.7%US$210.42US$74.46US$109.5011
Jan ’24US$124.75
US$145.47
+16.6%
25.8%US$207.20US$73.32US$107.2910
Dec ’23US$132.88
US$144.19
+8.5%
24.9%US$201.49US$71.30n/a11
Nov ’23n/a
US$139.30
0%
25.3%US$192.65US$68.17US$82.3811
Oct ’23US$102.06
US$139.60
+36.8%
25.0%US$194.44US$68.80US$88.0011
Sep ’23US$120.40
US$147.08
+22.2%
25.5%US$199.04US$70.43n/a11
Aug ’23US$145.48
US$146.79
+0.9%
26.0%US$199.41US$70.56US$115.6211
Jul ’23US$123.00
US$159.23
+29.5%
27.0%US$227.54US$73.02n/a11
Jun ’23US$135.25
US$170.01
+25.7%
27.4%US$230.74US$74.05US$116.0012
May ’23n/a
US$171.07
0%
27.1%US$231.93US$74.43US$137.2512

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.